CHUGAI-PHARMACEUTICAL
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai located in London, changed its corporate name to Chugai Pharma Europe Ltd. (CPE) effective from November 27.
The name change is part of Chugai’s reorganization to accelerate its overseas operation as announced on June 25 . In the reorganization, Chugai integrated and gathered its development and commercial entities in Europe that had been separated subsidiaries into one single company. Now under the name of Chugai Pharma Europe, the company will function as Chugai’s European hub to lead clinical development, regulatory affairs, medical affairs, import, sales and marketing of pharmaceutical products in Europe.
“We have now formed a new European Headquarters organization that will enhance our abilities to strongly advance our activities in Europe. Our scope includes conducting clinical trials for investigational drugs from Chugai as well as marketing collaboration with Roche for a rheumatoid arthritis agent RoActemra® and an upcoming new drug.” said John Halls, Managing Director of CPE. “I’m convinced that we will contribute to Chugai's aspiration to become a global company.”
With further streamlined operations, CPE will pursue its effort to add exceptional value through innovative medical products and services for the benefit of the medical community and human health around the world.
About Chugai Pharmaceutical Co., Ltd. (Chugai)
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area. In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe. The consolidated revenue in 2014 of Chugai totaled 461.1 billion yen and the operating income was 77.3 billion yen (IFRS Core basis).
Additional information is available on the internet at http://www.chugai-pharm.co.jp/english .
About Chugai Pharma Europe Ltd. (CPE)
Chugai Pharma Europe based in London, is the headquarters of all Chugai’s clinical development, regulatory affairs, medical affairs, import, sales and marketing of pharmaceutical products in Europe and coordinates the European marketing operations through subsidiaries located in the UK, France, and Germany. Products which are currently marketed in those countries include “RoActemra® (tocilizumab)”, a humanized anti-human IL-6 receptor monoclonal antibody, “Granocyte® (lenograstim)”, a G-CSF preparation, “Antepsin® (sucralfate)”, an antiulcer agent (marketed in the UK and Ireland), “Akynzeo® (netupitant-palonosetron)”, and “Aloxi® (palonosetron)” antiemetic agents (marketed in the UK). Furthermore, CPE is conducting the clinical development of SA237, an anti-IL-6 receptor humanized monoclonal antibody for the treatment of neuromyelitis optica, and CIM331, an anti-IL-31 receptor humanized monoclonal antibody for the treatment of atopic dermatitis.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151130005365/en/
Contact:
For Media
Chugai Pharmaceutical Co.,
Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki
Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For
European media
Chugai Pharma France SAS
Nathalie Leroy
Tel:
+33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For
Investors
Chugai Pharmaceutical Co., Ltd.
Investor
Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel:
+81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DentalMonitoring Launches "Top Ortho Practice Award" to Recognize Data-Driven Excellence in Orthodontic Care20.6.2025 19:08:00 CEST | Press release
DentalMonitoring, the global leader in AI-powered remote monitoring for orthodontics, is proud to announce the launch of the Top Ortho Practice Award, the first-of-its-kind recognition program that celebrates top-performing orthodontic practices worldwide through objective, data-based analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620540366/en/ Unlike traditional awards based on subjective nominations or popularity, the Top Ortho Practice Award is rooted in objective metrics derived from millions of patient scans and clinical interactions. Practices are selected based on exceptional outcomes in hygiene, compliance, and treatment effectiveness, using standardized benchmarks that reflect regional and global performance levels. The program identifies and celebrates practices that lead their territories in performance metrics derived from actual patient data, including hygiene, clinical techniques, and post-treatmen
SLB Announces Second-Quarter 2025 Results Conference Call20.6.2025 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 18, 2025 to discuss the results for the second quarter ending June 30, 2025. The conference call is scheduled to begin at 9:30 am U.S. Eastern time and a press release regarding the results will be issued at 7:00 am U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 719185. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/492107617 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 25, 2025, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
TH Global Capital Named 'Boutique Investment Banking Firm of the Year' for the Third Year Running at the 16th Annual International M&A Awards20.6.2025 18:18:00 CEST | Press release
TH Global Capital, a global boutique investment banking firm with operations across 13 countries in the Americas, Europe, and Asia-Pacific, with a track record of closing transactions in 29 countries, has won four prestigious awards at the 16th Annual International M&A Awards, including ‘Boutique Investment Banking Firm of the Year’ for the third consecutive year. TH Global Capital’s awards include: Boutique Investment Banking Firm of the Year 2025 Corporate/Strategic Deal of the Year ($50MM-$100MM): For advising Cloobees, a Global Salesforce Summit Partner in Poland, on its strategic sale to New York headquartered Synechron. Regional Deal of the Year – Asia: For advising Brainvire, a leading global Digital Commerce and Digital Marketing agency in Asia, on its merger with Said Differently, a Falfurrias portfolio company in the US. M&A Deal of the Year ($50MM–$100MM): For advising Chamonix IT and Exposé, leading Australian companies in Digital Engineering and AI & Data Science respectiv
Kuwait Celebrates National Day at Expo 2025 Osaka with a Striking Showcase of Culture, Vision and Purpose20.6.2025 15:03:00 CEST | Press release
The State of Kuwait marked its National Day at Expo 2025 Osaka, Kansai, with a celebration that captivated audiences and strengthened the pavilion’s growing reputation as one of the most compelling destinations at the global event. The day’s activities brought together dignitaries, Expo visitors and international media in a vibrant tribute to Kuwait’s heritage, identity and forward-looking vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620543251/en/ Kuwait celebrates National Day at Expo 2025 Osaka with a striking showcase of culture, vision and purpose (Photo: AETOSWire). The celebrations began with a parade featuring more than 100 participants, dressed in traditional attire and accompanied by music and movement. The procession drew large crowds across the Expo site, attracting attention for its energy, colour and cultural authenticity. The official ceremony took place at the National Day Hall within the Expo pre
HTEC Opened a New Office in Budapest, Signaling Further Expansion on the Hungarian Tech Scene20.6.2025 12:40:00 CEST | Press release
HTEC, a global AI-first company and a provider of technology design and engineering services, has opened a new office space in central Budapest, marking another step in the company’s strategic expansion across the Hungarian market. Located at Erzsébet krt. 2, the new space will serve as a hub for innovation and collaboration, welcoming new employees eager to shape the future of technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250620636346/en/ HTEC's Hungarian team at the opening of the company's new Budapest office HTEC partners with leading global companies to solve complex business problems in Financial Services, MedTech, Advanced Technologies, Retail, Telecommunications, and Enterprise Software & Platforms. Its end-to-end expertise—from product strategy to design and delivery—positions the company as a true extension of its clients’ teams. With a focus on strong partnerships and delivering measurable ROI fast, H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom